While neurogranin has been extensively studied as a cerebrospinal fluid (CSF) biomarker in Alzheimer’s disease and other neurodegenerative conditions [6,7], its utility in the context of mTBI is a relatively nascent field. This evidence concerns the gene NRGN and early-onset autosomal dominant Alzheimer disease.